Project Name: Rozšíření výzkumné a vývojové kapacity společnosti QUINTA-ANALYTICA, s.r.o.

Project Number: CZ.01.1.02/0.0/0.0/20_338/0023928

EUROPEAN UNION, European Regional Development Fund, OP Enterprise and Innovation for Competitiveness

The purpose of the project was to built a new research and development laboratory in Brno, which led to the expansion of the existing research and innovation capacity. In the frame of this significant project a top workplace equipped with the latest instruments and equipment for the analysis of medicinal products was created.

The research infrastructure is available to other users as a commercial service.

The list of the technologies offered for R&D purposes:

  • Liquid chromatograph 1260 + ELS detector
  • Liquid chromatograph 1260 + VW detector
  • H-Class Liquid Chromatograph
  • H-Class liquid chromatograph + RI detector
  • Agilent 8890 Gas Chromatograph with Mass Detector
  • GC/MS/MS Instrument
  • LCMS instrument with accessories
  • Fully automated dissolution system including UV spectrometer
  • Xtend on/offline with FS and SAM including spectrophotometer – UV7
  • Microbalances
  • Analytical balances
  • Hardness Tester, Disintegrator Tester
  • Centrifuge
  • Particle size analyser
  • Laminar box for particle sizer
  • Sleeve isolator
  • Oscillating Ball Mill
  • Fire-resistant chemical storage box
  • LIMS system

Further information are available upon request on robert.khaddour@quinta.cz.

Additional News

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.